Here are the 8-K filings from Goldenwell Biotech Inc (GWLL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow GWLL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GWLL filings page.
Goldenwell Biotech, Inc. (GWLL) appointed Ming Zhou as a director on October 8, 2026, bringing its board to four members. In connection with the appointment, Chief Executive Officer and director Shuang Liu gifted Zhou 20,000,000 common shares, equivalent to approximately 20.2% of the company’s issued and outstanding common stock. Zhou has served as managing director of Get Health Co., Ltd. and Get Intertrading Co., Ltd. since 2021. Her experience includes health products, nutritional supplements, herbal products, cosmetics, distribution, trading, warehousing and direct sales. She received an associate’s degree in Business Administration after attending China Central Radio and TV University from 1991 to 1993.
Goldenwell Biotech, Inc. dismissed Michael Gillespie & Associates, PLLC as its independent registered public accounting firm on September 27, 2026. The board had resolved on September 22, 2026, to engage Privatco CPA Limited as the new independent public accountants, and Privatco accepted.
The former auditor’s reports on the company’s 2025 and 2024 financial statements contained no adverse opinion or disclaimer and were not qualified or modified as to uncertainty, audit scope, or accounting principle. They stated substantial doubt about Goldenwell’s ability to continue as a going concern. Goldenwell reported no disagreements with the former auditor and no reportable events through the dismissal, and it had not consulted Privatco during the two most recent fiscal years or the interim period before the engagement.
Goldenwell Biotech, Inc. is alerting investors that certain prior quarterly financial statements should no longer be relied upon and will be restated to correct accounting errors. Its auditor determined a $9,840 legal invoice covering services from May 21, 2024 to September 23, 2025 was recorded in the wrong periods.
The company plans to amend its March 31, 2025 Form 10‑Q to recognize $2,280 of legal fees, its June 30, 2025 Form 10‑Q to recognize $2,200, and its September 30, 2025 Form 10‑Q to recognize $2,080. Goldenwell also identified errors in the timing of revenue recognition on a service contract and misclassified prepaid fees to OTC Markets Group, Inc. that should have been deferred and amortized over the contract term.
Because of these issues, the company states that the financial statements in its March 31, June 30, and September 30, 2025 Forms 10‑Q should not be relied upon insofar as they relate to the legal expenses accrued over that period. Goldenwell has discussed the matter with its independent registered public accounting firm, Michael Gillespie & Associates, PLLC, and expects to complete the restatements around June 30, 2026.